Market Closed -
Swiss Exchange
11:30:44 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
9.31
CHF
|
-0.64%
|
|
-2.00%
|
-5.10%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
71.48
|
126
|
53.93
|
55.82
|
75.32
|
85.79
|
85.79
|
Enterprise Value (EV)
1 |
49.5
|
94.65
|
112.7
|
55.82
|
75.32
|
85.79
|
85.79
|
P/E ratio
|
-0.86
x
|
-6.55
x
|
-0.55
x
|
-0.82
x
|
-1.18
x
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.26
x
|
1.67
x
|
3.59
x
|
-35
x
|
10.1
x
|
10.3
x
|
1.68
x
|
EV / Revenue
|
2.26
x
|
1.67
x
|
3.59
x
|
-35
x
|
10.1
x
|
10.3
x
|
1.68
x
|
EV / EBITDA
|
-1,499,103
x
|
-22,219,616
x
|
-1,173,946
x
|
-1,410,932
x
|
-1,788,232
x
|
-
|
-
|
EV / FCF
|
-1,632,835
x
|
50,463,532
x
|
-1,238,515
x
|
-1,494,203
x
|
-2,527,662
x
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
Price to Book
|
1.67
x
|
5.87
x
|
-
|
34.2
x
|
-2.13
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,060
|
1,111
|
1,926
|
4,197
|
5,458
|
9,215
|
9,215
|
Reference price
2 |
67.40
|
113.4
|
28.00
|
13.30
|
13.80
|
9.310
|
9.310
|
Announcement Date
|
4/29/19
|
3/24/20
|
4/29/21
|
6/10/22
|
4/27/23
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
31.66
|
75.38
|
15.01
|
-1.595
|
7.473
|
8.29
|
51.09
|
EBITDA
|
-47.68
|
-5.671
|
-45.94
|
-39.57
|
-42.12
|
-
|
-
|
EBIT
1 |
-51.42
|
-10.44
|
-53.08
|
-56.89
|
-51.98
|
-48.01
|
-32.64
|
Operating Margin
|
-162.43%
|
-13.85%
|
-353.65%
|
3,566.65%
|
-695.52%
|
-579.11%
|
-63.89%
|
Earnings before Tax (EBT)
|
-53.86
|
-18.39
|
-67.46
|
-54.72
|
-69.69
|
-
|
-
|
Net income
|
-54.19
|
-18.97
|
-67.66
|
-55.53
|
-70.15
|
-
|
-
|
Net margin
|
-171.17%
|
-25.17%
|
-450.82%
|
3,481.25%
|
-938.66%
|
-
|
-
|
EPS
|
-78.60
|
-17.30
|
-50.80
|
-16.20
|
-11.70
|
-
|
-
|
Free Cash Flow
|
-43.77
|
2.497
|
-43.54
|
-37.36
|
-29.8
|
-
|
-
|
FCF margin
|
-138.28%
|
3.31%
|
-290.14%
|
2,342.38%
|
-398.73%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/19
|
3/24/20
|
4/29/21
|
6/10/22
|
4/27/23
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
---|
Net sales
1 |
2.05
|
2.4
|
5.7
|
10.3
|
13.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.57
|
-13.49
|
-
|
-
|
-
|
Operating Margin
|
-613.07%
|
-562.17%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
58.8
|
-
|
-
|
-
|
-
|
Net Cash position
|
22
|
31.4
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-1.279
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-43.8
|
2.5
|
-43.5
|
-37.4
|
-29.8
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
40.40
|
19.30
|
-
|
0.3900
|
-6.490
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-32.70
|
-
|
-
|
-
|
-
|
Capex
|
1.35
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
4.26%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/19
|
3/24/20
|
4/29/21
|
6/10/22
|
4/27/23
|
-
|
-
|
Last Close Price
9.31
CHF Average target price
30
CHF Spread / Average Target +222.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.10% | 94.83M | | +5.48% | 71.19B | | +12.55% | 9.3B | | -13.75% | 5.01B | | +42.38% | 4.47B | | +4.51% | 3.96B | | -19.05% | 2.41B | | -28.72% | 2.23B | | +11.13% | 2.02B | | +6.53% | 1.69B |
Specialty & Advanced Pharmaceuticals
|